Navigation Links
A potential therapeutic agent for hepatic fibrosis
Date:8/25/2009

Accumulating evidence suggests that connective tissue growth factor (CCN2) plays a central role in fibrotic conditions in many organ systems. Fibrosis is a scarring condition that is characterized by excessive collagen production that impedes normal cell function and can cause organ dysfunction and failure. A hallmark of fibrosing injury in the liver is the activation of hepatic stellate cells (HSCs) which become highly proliferative, synthesize increased levels of transforming growth factor (TGF)-β and CCN2, and produce excessive amounts of collagen. Previous studies have not investigated the effect of CCN2 antagonism in HSCs of human origin.

A research team led by Dr. David Brigstock addresses this question. Their work will be published on August 14, 2009 in World Journal of Gastroenterology.

By designing a novel antisense inhibitor that blocked CCN2 mRNA transcription and protein production, the investigators showed that in activated human HSCs, basal or TGF-β1-induced transcription and production of collagen I could be reduced, and the ability of the cells to actively divide was curtailed. The innovative features of this study involve the use of human HSCs and the delivery of the antisense molecule in the form of a hammerhead ribozyme, which has a more efficient blocking action than some other conventional antisense methods. The data show that the anti-fibrotic properties of CCN2 hammerhead ribozyme are to the result of a reduction of collagen production and cell proliferation.

The results suggest that CCN2 hammerhead ribozyme has utility as a therapeutic agent for treating hepatic fibrosis in vitro. This is important as therapy for liver fibrosis is currently lacking despite the fact that millions of individuals around the world suffer from liver fibrosis caused by hepatitis, alcohol consumption, and other types of chronic liver injury.


'/>"/>

Contact: Lai-Fu Li
wjg@wjgnet.com
0086-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Herb Shows Potential for Rheumatoid Arthritis
2. Hissey Kientz, LLP Warns Duragesic Patch Users about Potential Health Risks of Fentanyl Overdose
3. ARKRAY Statement Regarding U.S. Food and Drug Administrations Public Health Notification: Potentially Fatal Errors With GDH-PQQ Glucose Monitoring Technology
4. Researchers identify potential new avenue to attack cancer
5. OcumatRx Announces Promising Clinical Trial Results for Implant with Potential to Permanently Treat Glaucoma
6. Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market
7. Large Majority of Drivers 55 and Older Unaware of Potentially Dangerous Combination of Medications and Driving, Says New AAA Foundation Study
8. New class of compounds discovered for potential Alzheimers disease drug
9. Consumer Reports Swine Flu Survival Kit Prepares Consumers for Potentially Tough Flu Season This Fall
10. Employers Recognize Potential Impact of Employee Health Management on Future Plan Costs
11. Hard to Treat Diseases (HTDS) To Re Release European TV Segment In N. America For Potential Treatment Of MS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology: